NeuroPhage is a biotechnology company focusing on a unique approach for treating diseases involving protein aggregation. NeuroPhage was founded in 2007 by a Cambridge-based team along with Professor Beka Solomon, Chair for Biotechnology of Neurodegenerative Diseases at Tel Aviv University.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/08/12 | $9,000,000 | Series B-1 | ||
| 05/06/13 | $6,400,000 |
Merieux Developpement Shire Strategic Investment Group | undisclosed | |
| 01/14/15 | $10,000,000 | Series D Extension |
